Aclaris Therapeutics Stock Investor Sentiment

ACRS Stock  USD 3.96  0.11  2.70%   
Slightly above 58% of all Aclaris Therapeutics' private investors are looking to take a long position. The analysis of overall sentiment of trading Aclaris Therapeutics stock suggests that some investors are interested at this time. Aclaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Aclaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Aclaris Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Aclaris Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at finance.yahoo.com         
Acquisition by Mehra Anand of 4793 shares of Aclaris Therapeutics subject to Rule 16b-3
Yahoo News
over six months ago at news.google.com         
Disposition of 9466 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 4660 shares by Schiff Andrew N of Aclaris Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Aclaris Therapeutics, Inc. Short Interest Down 18.2 percent in May - MarketBeat
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Kevin Balthaser of 59000 shares of Aclaris Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Aclaris Therapeutics, Inc. Receives Consensus Rating of Hold from Brokerages - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Aclaris Therapeutics Stock Passes Below Fifty Day Moving Average of 1.21 - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Aclaris Therapeutics, Inc. Short Interest Update - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Monaco Asset Management SAM Invests 1.03 Million in Aclaris Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Earnings Update Aclaris Therapeutics, Inc. Just Reported And Analysts Are Boosting Their Estimates
Yahoo News
over six months ago at simplywall.st         
Aclaris Therapeutics First Quarter 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over six months ago at investorplace.com         
ACRS Stock Earnings Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024
sbwire news
over six months ago at finance.yahoo.com         
Aclaris Therapeutics, Inc. Q1 2024 Earnings Call Transcript
Yahoo News
over six months ago at insidermonkey.com         
Aclaris Therapeutics, Inc. Q1 2024 Earnings Call Transcript
insidermonkey News
over six months ago at finance.yahoo.com         
American Clinical Research Services Announces Strategic Acquisition of Elixia
Yahoo News
Far too much social signal, news, headlines, and media speculation about Aclaris Therapeutics that are available to investors today. That information is available publicly through Aclaris media outlets and privately through word of mouth or via Aclaris internal channels. However, regardless of the origin, that massive amount of Aclaris data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Aclaris Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Aclaris Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Aclaris Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Aclaris Therapeutics alpha.

Aclaris Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITKJAK3 Inhibitor for the Treatment ...
09/17/2024
2
Disposition of 9467 shares by Walker Neal of Aclaris Therapeutics subject to Rule 16b-3
10/01/2024
3
Citadel Advisors LLC Adjusts Position in Aclaris Therapeutics Inc
11/15/2024
4
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
11/18/2024
5
Aclaris stock boosted by BTIG on transformative AD drug acquisition and outlook
11/19/2024
6
Aclaris Therapeutics director acquires 1.5 million in stock
11/20/2024
7
Acquisition by Leonard Braden Michael of 206025 shares of Aclaris Therapeutics at 1.2443 subject to Rule 16b-3
11/21/2024
8
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/26/2024

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.